JP2016514688A5 - - Google Patents

Download PDF

Info

Publication number
JP2016514688A5
JP2016514688A5 JP2016503074A JP2016503074A JP2016514688A5 JP 2016514688 A5 JP2016514688 A5 JP 2016514688A5 JP 2016503074 A JP2016503074 A JP 2016503074A JP 2016503074 A JP2016503074 A JP 2016503074A JP 2016514688 A5 JP2016514688 A5 JP 2016514688A5
Authority
JP
Japan
Prior art keywords
hydrate
prodrug
solvate
polymorph
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503074A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514688A (ja
JP6433482B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/029362 external-priority patent/WO2014144801A1/en
Publication of JP2016514688A publication Critical patent/JP2016514688A/ja
Publication of JP2016514688A5 publication Critical patent/JP2016514688A5/ja
Application granted granted Critical
Publication of JP6433482B2 publication Critical patent/JP6433482B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503074A 2013-03-15 2014-03-14 認知機能を改善するための方法および組成物 Active JP6433482B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361800191P 2013-03-15 2013-03-15
US61/800,191 2013-03-15
PCT/US2014/029362 WO2014144801A1 (en) 2013-03-15 2014-03-14 Methods and compositions for improving cognitive function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018101373A Division JP6808679B2 (ja) 2013-03-15 2018-05-28 認知機能を改善するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2016514688A JP2016514688A (ja) 2016-05-23
JP2016514688A5 true JP2016514688A5 (OSRAM) 2017-04-20
JP6433482B2 JP6433482B2 (ja) 2018-12-05

Family

ID=51537797

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016503074A Active JP6433482B2 (ja) 2013-03-15 2014-03-14 認知機能を改善するための方法および組成物
JP2018101373A Active JP6808679B2 (ja) 2013-03-15 2018-05-28 認知機能を改善するための方法および組成物
JP2019144290A Active JP7084632B2 (ja) 2013-03-15 2019-08-06 認知機能を改善するための方法および組成物
JP2020207747A Pending JP2021046438A (ja) 2013-03-15 2020-12-15 認知機能を改善するための方法および組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018101373A Active JP6808679B2 (ja) 2013-03-15 2018-05-28 認知機能を改善するための方法および組成物
JP2019144290A Active JP7084632B2 (ja) 2013-03-15 2019-08-06 認知機能を改善するための方法および組成物
JP2020207747A Pending JP2021046438A (ja) 2013-03-15 2020-12-15 認知機能を改善するための方法および組成物

Country Status (10)

Country Link
US (1) US11160785B2 (OSRAM)
EP (1) EP2968220B1 (OSRAM)
JP (4) JP6433482B2 (OSRAM)
CN (1) CN105142623A (OSRAM)
AU (3) AU2014228512A1 (OSRAM)
CA (1) CA2904767C (OSRAM)
DK (1) DK2968220T3 (OSRAM)
ES (1) ES2881081T3 (OSRAM)
HK (1) HK1218623A1 (OSRAM)
WO (1) WO2014144801A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2465948T3 (es) * 2010-04-30 2014-06-09 Exiqon A/S Procedimiento de hibridación in situ y tampón
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
RU2578446C1 (ru) * 2014-12-15 2016-03-27 государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации Способ активации когнитивных функций у лабораторных животных
CN112843005B (zh) 2015-05-22 2023-02-21 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
MA50634A (fr) * 2015-05-22 2021-04-28 Agenebio Inc Compositions pharmaceutiques à libération prolongée comportant du lévétiracétam
CN111172274B (zh) * 2020-01-22 2021-10-15 清华大学 Synaptotagmin-7在双向情感障碍诊断和治疗中的用途

Family Cites Families (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL181407B (nl) 1952-09-20 Merck & Co Inc Verbetering van een werkwijze ter bereiding van een farmaceutisch preparaat met antibacteriele werking, dat een combinatie van een verbinding van het 3-fluor-d-alaninetype en een cycloserineverbinding bevat.
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
GB1309692A (en) 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
JP2000319257A (ja) 1969-01-06 2000-11-21 Eisai Co Ltd 1−ベンジル−4−[(5,6−ジメトキシ−2−フルオロ−1−インダノン)−2−イル]メチルピペリジン
IT1045043B (it) 1975-08-13 1980-04-21 Isf Spa Derivati pirrolidinici
IT1075280B (it) 1977-02-11 1985-04-22 Isf Spa Procedimento per la preparazione di derivati pirrolidinici
BE864269A (fr) 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
DE2960194D1 (en) 1978-05-08 1981-04-16 Ucb Sa Lactam-n-acetic acids, their amides, process for their preparation and therapeutic compositions containing them
US4654370A (en) 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4372960A (en) 1980-12-12 1983-02-08 Warner-Lambert Company Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators
FR2515179A1 (fr) 1981-07-24 1983-04-29 Hoffmann La Roche Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
IL67623A (en) 1983-01-05 1984-09-30 Teva Pharma 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
IL72381A (en) 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US4558070A (en) 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
US4668687A (en) 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
US4913906B1 (en) 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
JPS6222785A (ja) 1985-07-23 1987-01-30 Sanwa Kagaku Kenkyusho:Kk 新規な2−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
IT1190133B (it) 1986-06-19 1988-02-10 Chiesi Farma Spa Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4816456A (en) 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
EP0363415B1 (en) 1987-05-04 2008-10-15 Davis, Bonnie Compounds for the treatment of alzheimer's disease
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
IL85741A (en) 1987-03-17 1996-05-14 Hoechst Roussel Pharma Substituted tetrahydroacridines a process for their preparation and pharmaceutical compositions containing substituted alpha-amino-tetrahydroacridines
DE3709230A1 (de) 1987-03-20 1988-10-06 Desitin Arzneimittel Gmbh Neues calciumsalz der valproinsaeure
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
US5002955A (en) 1987-04-23 1991-03-26 Hoechst-Roussel Pharmaceuticals Inc. Fused heteroalkylene quinolinamines and use as cholinergic agents
US5187165A (en) 1987-05-15 1993-02-16 Hoechst-Roussel Pharmaceuticals Inc. Memory enhancing and analgesic 1,2,3a,8,8a-hexahydro-3a,8(and 1,3a,8)-di(and tri)methylpyrrolo[2,3-b]indoles
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JPS6422883A (en) 1987-07-17 1989-01-25 Sanwa Kagaku Kenkyusho Co 1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient
DE3773926D1 (de) 1987-07-22 1991-11-21 Farvalsa Ag Feuchtigkeitsstabile feste valproinsaeure-zubereitung und verfahren zu ihrer herstellung.
US4950658A (en) 1988-12-06 1990-08-21 Board Of Trustees Of Southern Illinois Univ. Method of medical treatment of Alzheimer's disease
CA2007732A1 (en) 1989-01-17 1990-07-17 Gary L. Olson Cyclohexaneacetamide derivatives
FR2643556B1 (fr) 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
US4981870A (en) 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US5238945A (en) 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
US5364866A (en) 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5693668A (en) 1989-06-22 1997-12-02 Merrell Pharmaceuticals Inc. Acetylcholinesterase inhibitors
EP0403713A1 (en) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Novel acetylcholinesterase inhibitors
IT1231477B (it) 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
US4999430A (en) 1989-07-31 1991-03-12 Warner-Lambert Company Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine
DE3927049A1 (de) 1989-08-16 1991-02-21 Sandoz Ag Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung
US5387590A (en) 1989-08-30 1995-02-07 Pfizer Inc. Benzazabicyclic carbamates as novel cholinesterase inhibitors
US4914102A (en) 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
EP0445095A1 (en) 1990-03-02 1991-09-04 Uni Patent Ab Equipment for preventing separation in bulk materials
NZ237241A (en) 1990-03-02 1993-11-25 Pharmetrix Corp Method for increasing the storage stability of physostigmine
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
US5102891A (en) 1990-07-23 1992-04-07 Hoechst-Roussel Pharmaceuticals Inc. 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
US5264442A (en) 1990-08-13 1993-11-23 Hoechst-Roussel Pharmaceuticals Incorporated Carbamoyl-1-(pyridinylalkyl)-1H-indoles, indolines and related analogs
TW200462B (OSRAM) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
JP2965675B2 (ja) 1990-11-21 1999-10-18 エーザイ株式会社 (―)―1―ベンジル―4―〔(5,6―ジメトキシ―1―インダノン)―2―イル〕メチルピペリジンの製造方法
TW197435B (OSRAM) 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
FI934223L (fi) 1991-03-28 1993-09-27 Pfizer Heterocykliscykliska aminderivat
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
US5104880A (en) 1991-05-01 1992-04-14 Mayo Foundation For Medical Education And Research Huperzine a analogs as acetylcholinesterase inhibitors
CA2067614C (en) 1991-05-02 2002-07-30 Eiichi Otomo Agent for improving dementia
FR2677019B1 (fr) 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
US5106856A (en) 1991-06-07 1992-04-21 Hoechst-Roussel Pharmaceuticals Inc. [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
FR2679555B1 (fr) 1991-07-25 1993-11-19 Fabre Medicament Pierre Nouveaux derives de l'uree, leur preparation et leur application en therapeutique.
WO1993003034A1 (en) 1991-07-29 1993-02-18 Warner-Lambert Company Quinazoline derivatives as acetylcholinesterase inhibitors
IT1251166B (it) 1991-08-09 1995-05-04 Chiesi Farma Spa Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
US5246947A (en) 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
US5231093A (en) 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
TW263504B (OSRAM) 1991-10-03 1995-11-21 Pfizer
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
EP0619814A1 (en) 1991-12-31 1994-10-19 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
AU4275793A (en) 1992-02-25 1993-09-13 Warner-Lambert Company Cytoprotective compositions containing pyruvate and antioxidants
US5439930A (en) 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
IT1254996B (it) 1992-06-25 1995-10-11 Mediolanum Farmaceutici Srl Esteri amminoalchilcarbammici dell'eserolina atti all'impiego come anticolinesterasici e relativo procedimento di preparazione
US5440023A (en) 1992-09-18 1995-08-08 Beckman Instruments, Inc. Method for making valproic acid derivatives
TW251284B (OSRAM) 1992-11-02 1995-07-11 Pfizer
EP0611769A1 (en) 1993-02-16 1994-08-24 Merrell Dow Pharmaceuticals Inc. Silylated acetylcholinesterase inhibitors
WO1994020476A1 (fr) 1993-03-02 1994-09-15 Fujisawa Pharmaceutical Co., Ltd. Nouveau compose heterocyclique
EP0627400A1 (en) 1993-06-04 1994-12-07 Merrell Dow Pharmaceuticals Inc. Aromatic acetylcholinesterase inhibitors
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
GB9319732D0 (en) 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US5744476A (en) 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
US5603176A (en) 1995-02-27 1997-02-18 Hasbro, Inc. Simulated suspended animation biosphere
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
IL115113A (en) 1995-08-31 2002-11-10 Israel State 3-carbamoyloxy pyridinium derivatives and pharmaceutical compositions containing them
ES2100129B1 (es) 1995-10-11 1998-02-16 Medichem Sa Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
ES2197255T3 (es) 1995-11-17 2004-01-01 MERCK & CO. INC. Nuevos compuestos de arilo sustituido utiles como moduladores de los receptores de acetilcolina.
US5783584A (en) 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
WO1997038993A1 (en) 1996-04-12 1997-10-23 Hoechst Marion Roussel, Inc. Isatin derivatives as acetylcholinesterase inhibitors and analgesics
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
WO1997046526A1 (en) 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
CA2180703A1 (en) 1996-07-08 1998-01-09 Paul Marie Victor Gilis Fast-dissolving galanthamine hydrobromide tablet
EA006626B1 (ru) 1996-07-24 2006-02-24 Дюпон Фармасьютикалз Компани Азолопиримидины, фармацевтическая композиция и способ лечения
WO1998007431A1 (en) 1996-08-22 1998-02-26 New York University Cholinesterase inhibitors for treatment of parkinson's disease
IT1285801B1 (it) 1996-10-10 1998-06-24 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione dell'acido valproico
AU5716898A (en) 1997-01-08 1998-08-03 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
US6455544B1 (en) 1997-03-03 2002-09-24 Eisai Co. Ltd. Use of cholinesterase inhibitors to treat disorders of attention
GB9716879D0 (en) 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
AU8742198A (en) 1997-08-15 1999-03-08 Shire International Licensing B.V. Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity
US6479523B1 (en) 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
WO1999029668A1 (en) 1997-12-05 1999-06-17 Eisai Co., Ltd. Donepezil polycrystals and process for producing the same
US6131106A (en) 1998-01-30 2000-10-10 Sun Microsystems Inc System and method for floating-point computation for numbers in delimited floating point representation
GB9805561D0 (en) 1998-03-16 1998-05-13 Merck Sharp & Dohme A combination of therapeutic agents
US6262081B1 (en) 1998-07-10 2001-07-17 Dupont Pharmaceuticals Company Composition for and method of treating neurological disorders
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
IL125809A (en) 1998-08-17 2005-08-31 Finetech Lab Ltd Process and intermediates for production of donepezil and related compounds
IT1304904B1 (it) 1998-09-11 2001-04-05 Eisai Co Ltd Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
ID28441A (id) 1998-10-16 2001-05-24 Janssen Pharmaceutica Nv Terapi untuk memperbaiki kesadaran
JP5558648B2 (ja) 1998-11-23 2014-07-23 デイビス、ボニー アセチルコリンエステラーゼ阻害剤のための投与製剤
EP1137414B1 (en) 1998-12-11 2005-10-12 Bonnie M. Davis Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
US6277866B1 (en) 1999-03-03 2001-08-21 Eisai Co., Ltd. 1-benzyl-4[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine
ES2211056T3 (es) 1999-03-31 2004-07-01 Eisai Co., Ltd. Composiciones estabilizadas que contienen farmacos nootropicos.
EP1050303A3 (en) 1999-04-27 2003-01-15 Pfizer Products Inc. Methods and compositions for treating age-related behavioral disorders in companion animals
AU6053900A (en) 1999-06-25 2001-01-31 Morris Notelovitz Compositions for treating or preventing neurodegeneration and cognitive decline
WO2001016105A1 (en) 1999-09-01 2001-03-08 Eisai Co., Ltd. 4-substituted piperidine derivatives
JP4242048B2 (ja) 1999-09-01 2009-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 4−置換ピペリジン誘導体
EP1214299B1 (en) 1999-09-22 2004-04-14 Schering Corporation Muscarinic antagonists
US6620802B1 (en) 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
EE200200274A (et) 1999-12-01 2003-06-16 Ucb, S.A. Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
JP2003525903A (ja) 2000-03-03 2003-09-02 エーザイ株式会社 コリンエステラーゼ阻害剤の新規使用法
US20030144255A1 (en) 2000-03-06 2003-07-31 Bain Allen I Compositions for prevention and treatment of dementia
US6706741B2 (en) 2000-04-13 2004-03-16 Eisai Co., Ltd. Acetylcholinesterase inhibitors containing 1-benzyl-pyridinium salts
US20010036949A1 (en) 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
US6756385B2 (en) 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
US20020151591A1 (en) 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
US7608636B2 (en) 2000-12-28 2009-10-27 Hamilton Pharmaceuticals, Inc. Medicines for treatment and prevention of neurogenic pain
US6610326B2 (en) 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
WO2002067931A1 (en) 2001-02-23 2002-09-06 Johns Hopkins University Treatment of tics, tremors and related disorders
CA2442717A1 (en) 2001-03-15 2002-09-26 Saegis Pharmaceuticals, Inc. Methods for restoring cognitive function following systemic stress
EP1256578B1 (en) 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
WO2002094787A1 (en) 2001-05-23 2002-11-28 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
US8354438B2 (en) 2001-08-08 2013-01-15 Michael Chez Neurological functions
ES2311537T3 (es) 2001-08-22 2009-02-16 Hamilton Pharmaceuticals, Inc. Utilizacion de nefiracetam en el tratamiento de la neurodegeneracion postquemica.
WO2003020289A1 (en) 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
ATE444065T1 (de) 2001-10-16 2009-10-15 Memory Pharm Corp 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-deriva e als pde-4-hemmer zur behandlung von neurologischen syndromen
US6495700B1 (en) 2002-01-09 2002-12-17 Axonyx, Inc. Process for producing phenserine and its analog
US6759552B2 (en) 2002-03-28 2004-07-06 Council Of Scientific And Industrial Research Compound as cholinesterase inhibitor and its isolation from fungus sporotrichum species
JP4405811B2 (ja) 2002-03-29 2010-01-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 (1−インダノン)−(1,2,3,6−テトラヒドロピリジン)誘導体
WO2003091220A1 (en) 2002-04-26 2003-11-06 Schering Corporation Muscarinic antagonists
AU2003298514A1 (en) 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
PL373903A1 (en) 2002-05-31 2005-09-19 H.Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
US20040116506A1 (en) 2002-06-20 2004-06-17 Krusz John Claude Use of levetiracetam for treating or preventing acute headaches
US7557137B2 (en) 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
GB0223494D0 (en) 2002-10-09 2002-11-13 Neuropharma Sa Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease
AU2003274353B2 (en) 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
CA2589836A1 (en) 2002-11-22 2004-06-10 The Johns Hopkins University Target for therapy of cognitive impairment
JP2006516390A (ja) 2002-12-03 2006-07-06 ユ セ ベ ソシエテ アノニム 発作、神経系疾患、内分泌障害及びホルモン疾患の治療用薬剤の同定方法
US7090985B2 (en) 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
CA2508004A1 (en) 2002-12-11 2004-06-24 Pharmacia & Upjohn Company Llc Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
WO2004080393A2 (en) 2003-03-06 2004-09-23 Celgene Corporation Selective cytokine inhibitory drugs for treating disorders of the central nervous system
US20040191334A1 (en) 2003-03-24 2004-09-30 Pang-Chui Shaw Use of transhinone derivates as cholinesterase inhibitors in treating related diseases
ITMI20030573A1 (it) 2003-03-24 2004-09-25 Nikem Research Srl Composti ad azione nootropica, loro preparazione,
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
CN102000336A (zh) 2003-05-23 2011-04-06 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
US7244843B2 (en) * 2003-10-07 2007-07-17 Bristol-Myers Squibb Company Modulators of serotonin receptors
JP2007508288A (ja) 2003-10-08 2007-04-05 ファイザー株式会社 縮合ラクタム化合物
EP2269608A3 (en) 2003-10-16 2011-02-16 NeuroSearch AS Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
WO2005042475A2 (en) 2003-10-21 2005-05-12 Sention, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
WO2005054188A1 (en) 2003-12-02 2005-06-16 Ucb, S.A. Imidazole derivatives, processes for preparing them and their uses
US20050222123A1 (en) 2004-01-27 2005-10-06 North Shore-Long Island Jewish Research Institute Cholinesterase inhibitors for treating inflammation
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
EP1727538A2 (en) 2004-02-13 2006-12-06 Neuromolecular Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
JP2007529556A (ja) 2004-03-19 2007-10-25 アクソニクス インコーポレイテッド 認知障害の処置に有用なアセチルコリンエステラーゼ阻害剤およびn−メチル−d−アスパラギン酸拮抗剤
EP1740575A2 (en) 2004-04-22 2007-01-10 Eli Lilly And Company Pyrrolidine derivatives useful as bace inhibitors
WO2005120523A1 (en) 2004-06-04 2005-12-22 Mood Management Sciences, Llc Methods and compositions for treating mood disorder
US20070212428A1 (en) 2004-06-04 2007-09-13 Mood Management Sciences, Inc. Methods and compositions for treating mood disorder
CA2568700A1 (en) 2004-06-11 2005-12-22 Ucb, S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
US20060063707A1 (en) 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
WO2006040688A2 (en) 2004-10-12 2006-04-20 Ernir Snorrason Inhibitors of acetylcholinesterase for treating skin diseases
ES2361031T3 (es) 2004-10-18 2011-06-13 Eli Lilly And Company Benzopiranos sustituidos como agonistas selectivos del receptor beta de estrógenos.
WO2006060082A1 (en) 2004-10-22 2006-06-08 THE GOVERNMENT OF THE U.S.A. as represented by THE SEC., DEPT. OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH Tricyclic compounds, preparation thereof and use thereof as cholinesterase activity inhibitors
EP2425846A1 (en) 2004-12-23 2012-03-07 Voyager Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
WO2006070394A1 (en) 2004-12-28 2006-07-06 Council Of Scientific And Industrial Research Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors
EA014249B1 (ru) 2005-01-27 2010-10-29 Алембик Лимитед Формуляция леветирацетама длительного высвобождения
FR2881618B1 (fr) 2005-02-10 2007-04-13 Centre Nat Rech Scient Utilisation de composes derives de pyrimidinetrione en tant qu'inhibiteurs de l'acetylcholinesterase, compositions contenant ces derives et leurs utilisations en tant qu'insecticides
US20070298098A1 (en) 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
WO2006123357A2 (en) 2005-02-22 2006-11-23 Sun Pharmaceutical Industries Limited Oral controlled release composition containing levetiracetam
US8216611B2 (en) 2005-03-30 2012-07-10 Mylan Pharmaceuticals Ulc Combined-step process for pharmaceutical compositions
EP1874282B1 (en) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US20060241144A1 (en) 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
BRPI0608780A2 (pt) * 2005-04-28 2010-11-09 Eisai R&D Man Co Ltd composição contendo fármaco anti-demência
MX2007015052A (es) 2005-05-31 2008-01-18 Orexigen Therapeutics Inc Metodos y composiciones para manejar trastornos psicoticos.
EP2308867A3 (en) 2005-06-01 2011-10-19 UCB Pharma S.A. 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
EP1731149A1 (en) 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
HRP20141185T1 (hr) 2005-07-26 2015-01-30 Ucb Pharma Sa Farmaceutski pripravci koji sadrže levetiracetam i proces za njihovu pripremu
EP1924712B1 (en) 2005-08-03 2018-10-03 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
GB0517740D0 (en) 2005-08-31 2005-10-12 Novartis Ag Organic compounds
US20090018148A1 (en) 2005-12-07 2009-01-15 Ucb Pharma, S.A. Xanthine Derivatives, Processes For Preparing Them And Their Uses
CA2643199A1 (en) 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009531323A (ja) 2006-03-20 2009-09-03 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ アセチルコリンエステラーゼ阻害剤として有用な薬剤組成物
CA2650711A1 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
CN101506157B (zh) 2006-06-08 2013-07-24 Ucb医药有限公司 吡咯烷酮共结晶
US20080014271A1 (en) 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
EP2051696A2 (en) 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
WO2008062446A2 (en) 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
EP2076288A2 (en) 2006-09-22 2009-07-08 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
AU2007309390A1 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Methods and combination therapies for treating Alzheimer's disease
EP2114166A4 (en) 2006-12-11 2011-05-25 Reviva Pharmaceuticals Inc COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE-BASED CHOLINESTERASE INHIBITORS
WO2008074896A1 (en) 2006-12-21 2008-06-26 Prendergast Patrick T Compositions and methods for treatment of chronic neurological disorders
WO2008097546A2 (en) 2007-02-02 2008-08-14 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
FR2912056B1 (fr) 2007-02-05 2009-12-18 Rd Pharmagal Composition a liberation prolongee de levetiracetam et procede de preparation
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
US20100222326A1 (en) 2007-04-27 2010-09-02 Ucb Pharma, S.A. New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders
WO2008144305A1 (en) 2007-05-18 2008-11-27 Janssen Pharmaceutica N.V. Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators
RU2339620C1 (ru) 2007-07-09 2008-11-27 Общество С Ограниченной Ответственностью "Фармвинг" Оксалат n, n-диметил-2-n, n-диметиламинометилпиридил-3-карбамат, обладающий антихолинэстеразной активностью и способностью улучшать когнитивные функции
EP2164489A2 (en) 2007-07-13 2010-03-24 Eisai R&D Management Co., Ltd. Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
US20090030403A1 (en) 2007-07-27 2009-01-29 Leyde Kent W Methods and Systems for Attenuating the Tolerance Response to a Drug
WO2009038412A2 (en) 2007-09-21 2009-03-26 Lg Life Sciences, Ltd. Beta-secretase inhibiting compounds
US20090176740A1 (en) 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
WO2009082039A1 (en) 2007-12-26 2009-07-02 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
WO2009109547A1 (en) 2008-03-03 2009-09-11 Ucb Pharma, S.A. Pharmaceutical solutions, process of preparation and therapeutic uses
US20110212944A1 (en) 2008-07-01 2011-09-01 Julie Liu 2-oxo-1-pyrrolidine derivatives
JP2010024156A (ja) 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
CN102170874A (zh) 2008-08-06 2011-08-31 高思福斯中心(控股)有限公司 治疗精神病学障碍的组合物和方法
ES2865504T3 (es) 2008-10-16 2021-10-15 Univ Johns Hopkins Procedimientos y composiciones para la mejora de la función cognitiva
US9125898B2 (en) 2008-11-14 2015-09-08 Neurotune Ag Acetam derivatives for pain relief
US20100125094A1 (en) 2008-11-17 2010-05-20 Auspex Pharmaceuticals, Inc. Pyrrolidinyl modulators of nicotinic acetylcholine receptors
HUE032275T2 (en) 2008-11-18 2017-09-28 Ucb Biopharma Sprl Sustained release formulations containing a 2-oxo-pyrrolidine derivative
US20100172979A1 (en) 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
AU2010209790B2 (en) 2009-01-29 2014-01-16 Ucb Pharma, S.A. Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
EP2393483B1 (en) 2009-02-09 2017-06-28 UCB Biopharma SPRL Pharmaceutical compositions comprising brivaracetam
US8846411B2 (en) 2009-06-11 2014-09-30 Microgenics Corporation Derivatives, reagents, and immunoassay for detecting levetiracetam
EP2461808A2 (en) 2009-08-07 2012-06-13 UCB Pharma S.A. Methods for enhancing the cognitive function
CN101647789B (zh) 2009-09-01 2011-08-17 天津药物研究院药业有限责任公司 左乙拉西坦缓释微丸胶囊制剂
WO2011049309A2 (ko) * 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
US20110262442A1 (en) 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
EP2533645B1 (en) * 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2011143721A1 (en) * 2010-05-21 2011-11-24 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating neurodegenerative disorders
KR20120055313A (ko) 2010-11-23 2012-05-31 주식회사 바이오파마티스 레베티라세탐 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법
EP3400934A1 (en) 2011-02-09 2018-11-14 The Johns Hopkins University Levetiracetam for improving cognitive function
DE102011103270A1 (de) 2011-05-26 2012-11-29 Stada Arzneimittel Ag Pulverförmige Mischung zur Herstellung von Levetiracetam-haltigen Tabletten
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
CN104619175A (zh) 2012-08-08 2015-05-13 法莫泰克有限公司 延长释放左乙拉西坦和制备方法
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
US20160030391A1 (en) 2013-03-15 2016-02-04 The Johns Hopkins University Methods and compositions for improving cognitive function
CN104586806B (zh) 2014-12-26 2018-03-13 东北制药集团沈阳第一制药有限公司 一种左乙拉西坦缓释片及其制备方法
CN112843005B (zh) 2015-05-22 2023-02-21 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物

Similar Documents

Publication Publication Date Title
JP2016514688A5 (OSRAM)
JP2013518914A5 (OSRAM)
Marcinkowska et al. Management of dementia-related psychosis, agitation and aggression: a review of the pharmacology and clinical effects of potential drug candidates
CA2923685C (en) Application of r-ketamine and salt thereof as pharmaceuticals
US11439649B2 (en) Combination therapy with apilimod and glutamatergic agents
CA2789014A1 (en) Methods and compositions for improving cognitive function
JP5992049B2 (ja) 置換されたキナゾリノンのための経口速放性製剤
JP2014517050A5 (OSRAM)
JP2015528471A5 (OSRAM)
NZ630589A (en) Methods of treating alzheimer’s disease and pharmaceutical compositions thereof
JP2012530779A5 (OSRAM)
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
JP2016147915A5 (OSRAM)
JP2021505575A5 (OSRAM)
JP2015510916A5 (OSRAM)
SI2419104T1 (en) Combinations of 5-HT4 receptor agonists and acetylcholinesterase inhibitors for the treatment of cognitive disorders
JP2016539157A5 (OSRAM)
RU2013153140A (ru) Новая ассоциация между 4-{3-[цис-гексагидроциклопента[c] пиррол-2 (1н )- ил] пропокси} бензамидом и ингибитором ацетилхолинэстеразы и фармацевтические композиции, которые ее содержат
JP2008533142A (ja) α7ニューロンニコチン性受容体リガンドおよび抗精神病薬組成物
MA37721A1 (fr) Formes pharmaceutiques contenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phényl]-1,3-oxazolidin-5-yl}-méthyl)-2-thiophène-carboxamide
JP6436913B2 (ja) L−4−クロロキヌレニンの剤形及び治療的使用
JP2016520635A5 (OSRAM)
JP2008538582A (ja) 精神病性障害の治療または予防のための新規の治療的組み合わせ
JP2011513340A5 (OSRAM)
JP2024544500A (ja) 焦燥性興奮および他の認知症関連行動症状を治療する方法